Workers’ Comp MSA Costs Run 23% Below National Average Where Clinical Intervention Is Applied

Why It Matters

Lower MSA allocations directly reduce settlement exposure for employers and insurers, boosting profitability while maintaining compliance. The shift underscores the financial upside of integrating clinical oversight into MSP programs and the heightened risk of documentation lapses under new CMS rules.

Key Takeaways

• Clinical interventions cut MSA allocations 23% below national average
• 2025 average WCMSA $67,692 vs CMS average $86,169
• Pharmacy and opioid allocations dropped to 0 in majority of cases
• Conditional payment demands fell >90%, 82% eliminated in 2025
• Documentation standards critical after CMS stopped reviewing $0 MSAs

Pulse Analysis

The latest Tower MSA Partners analysis highlights a clear financial advantage for workers’ compensation payers that embed clinical oversight into their Medicare Secondary Payer (MSP) processes. By actively managing physician follow‑up and pharmacy utilization, these programs trimmed average Medicare Set‑Aside (MSA) allocations to $67,692 in 2025—roughly $18,500 per claim below the CMS benchmark. Over a portfolio handling 100 Medicare‑eligible claims annually, that differential translates into roughly $2 million of reduced settlement exposure, a compelling incentive for insurers and self‑funded employers to adopt medically driven compliance models.

Pharmacy and opioid cost management emerged as the most potent lever for savings. In 2025, 60% of CMS‑approved MSAs reported a $0 pharmacy allocation and 86% contained no opioid component, a stark contrast to prior years where medication costs inflated MSA projections. A highlighted case study showed a single file’s projected MSA slashed from $285,151 to $53,664 after a physician attested to actual medication use, delivering a $231,487 reduction. Across the 2022‑2025 window, such interventions generated $9‑$12 million in annual savings, underscoring the value of precise medication documentation and proactive care‑plan realignment.

Regulatory shifts in 2025 intensified the documentation burden. CMS expanded Section 111 reporting in April, increasing visibility into settlement patterns, and in July ceased reviewing $0 MSAs, placing full responsibility for zero‑allocation justification on payers. Consequently, 84%‑90% of submissions avoided development letters, and CMS review times fell from 23 to 15 days. However, incomplete medical records and missing prescription histories now pose the greatest risk of demand rejections. Stakeholders must therefore invest in robust data capture and structured decision frameworks to sustain the cost‑saving momentum while navigating the tighter compliance landscape.